Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Stein, Alexander ^a   Glockzin, Gabriel ^b   Wienke, Andreas ^c   Arnold, Dirk ^a   Edelmann, Thomas ^d   Hildebrandt, Bert ^e   Hollerbach, Stephan ^f   Illerhaus, Gerald ^g   Königsrainer, Alfred ^h   Richter, Michael ^c   Schlitt, Hans J ^b   Schmoll, Hans Joachim ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^d MedCenter Nordsachsen ^*  (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f Academic Teaching Hospital   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Bevacizumab; FOLFOXIRI; Metastatic colorectal cancer; Resectable liver metastases

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; ARTICLE; ASTHENIA; COLORECTAL CANCER; COLORECTAL LIVER METASTASIS; COLORECTAL SURGERY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAILURE FREE SURVIVAL; FEASIBILITY STUDY; FOLLOW UP; GERMANY; HUMAN; HYPERTENSION; LIVER METASTASIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; METASTASIS; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIOPERATIVE PERIOD; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MULTICENTER STUDIES AS TOPIC; ORGANOPLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84864912888     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-356     Document Type: Article

References (64)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917. 10.1002/ijc.25516, 21351269.
3. van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, Verhoef C. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis 2012, 14:56-61. 10.1111/j.1463-1318.2010.02539.x, 21176063.
4. Mantke R, Schmidt U, Wolff S, Kube R, Lippert H. Incidence of synchronous liver metastases in patients with colorectal cancer in relationship to clinico-pathologic characteristics. Results of a German prospective multicentre observational study. Eur J Surg Oncol 2012, 38:259-265. 10.1016/j.ejso.2011.12.013, 22209659.
5. Schmoll HJ, Sargent D. Single agent fluorouracil for first-line treatment of advanced colorectal cancer as standard?. Lancet 2007, 370:105-107. 10.1016/S0140-6736(07)61062-9, 17630019.
6. Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, et al. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009. Ann Oncol 2010, 21(uppl 6):vi1-10.
7. Schmiegel W, Pox C, Arnold D, Porschen R, Rodel C, Reinacher-Schick A. Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases. Dtsch Arztebl Int 2009, 106:843-848. 2803611, 20062582.
8. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009, 27:3677-3683. 10.1200/JCO.2008.20.5278, 2720081, 19470929.
9. Morris EJ, Forman D, Thomas JD, Quirke P, Taylor EF, Fairley L, Cottier B, Poston G. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010, 97:1110-1118. 10.1002/bjs.7032, 20632280.
10. Jonas S, Thelen A, Benckert C, Spinelli A, Sammain S, Neumann U, Rudolph B, Neuhaus P. Extended resections of liver metastases from colorectal cancer. World J Surg 2007, 31:511-521. 10.1007/s00268-006-0140-3, 17308854.
11. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol 2006, 13:668-676. 10.1245/ASO.2006.05.039, 16523369.
12. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007, 25:4575-4580. 10.1200/JCO.2007.11.0833, 17925551.
13. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg 1995, 19:59-71. 10.1007/BF00316981, 7740812.
14. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999, 230:309-318. discussion 318-321, 10.1097/00000658-199909000-00004, 1420876, 10493478.
15. Adam R, Barroso E. Impact of the type and modalities of preoperative chemotherapy on the outcome of liver resection for colorectal metastases. J Clin Oncol 2011, 29:abstr 3519.
16. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 2009, 250:440-448.
17. Nagashima I, Takada T, Nagawa H, Muto T, Okinaga K. Proposal of a new and simple staging system of colorectal liver metastasis. World J Gastroenterol 2006, 12:6961-6965.
18. Poston GJ, Figueras J, Giuliante F, Nuzzo G, Sobrero AF, Gigot JF, Nordlinger B, Adam R, Gruenberger T, Choti MA, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008, 26:4828-4833. 10.1200/JCO.2008.17.6453, 18711170.
19. Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006, 42:2212-2221. 10.1016/j.ejca.2006.04.012, 16904315.
20. Yamaguchi T, Mori T, Takahashi K, Matsumoto H, Miyamoto H, Kato T. A new classification system for liver metastases from colorectal cancer in Japanese multicenter analysis. Hepatogastroenterology 2008, 55:173-178.
21. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009, 20:985-992. 10.1093/annonc/mdn735, 19153115.
22. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008, 371:1007-1016. 10.1016/S0140-6736(08)60455-9, 2277487, 18358928.
23. Wong R, Cunningham D, Barbachano Y, Saffery C, Valle J, Hickish T, Mudan S, Brown G, Khan A, Wotherspoon A, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol 2011, 22:2042-2048. 10.1093/annonc/mdq714, 21285134.
24. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zielinski C, Herbst F, Gruenberger T. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008, 26:1830-1835. 10.1200/JCO.2007.13.7679, 18398148.
25. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006, 24:4976-4982. 10.1200/JCO.2006.06.8353, 17075115.
26. Langer B, Bleiberg H, Labianca R, et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002, 21(abstr 592):2002.
27. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008, 26:4906-4911. 10.1200/JCO.2008.17.3781, 18794541.
28. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009, 20:1964-1970. 10.1093/annonc/mdp236, 19567451.
29. Andre T, Van Cutsem E. A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial. J Clin Oncol 2011, 29:abstr 3509.
30. Voest EE, Snoeren N. A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer. J Clin Oncol 2011, 29:abstr 3565.
31. Allegra CJ, Yothers G, O'Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, Atkins JN, Seay TE, Fehrenbacher L, Goldberg RM, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011, 29:11-16. 10.1200/JCO.2010.30.0855, 3055856, 20940184.
32. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28:4697-4705. 10.1200/JCO.2009.27.4860, 20921465.
33. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, et al. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J Clin Oncol 2011, 29:2011-2019. 10.1200/JCO.2010.33.5091, 21502544.
34. Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008, 26:2013-2019. 10.1200/JCO.2007.14.9930, 18421054.
35. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114. 10.1016/S0140-6736(11)60613-2, 3159415, 21641636.
36. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel A, Celik I, Schlichting M, Koralewski P. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 22:1535-1546. 10.1093/annonc/mdq632, 21228335.
37. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007, 25:1670-1676. 10.1200/JCO.2006.09.0928, 17470860.
38. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342. 10.1056/NEJMoa032691, 15175435.
39. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol 2009, 20:1842-1847. 10.1093/annonc/mdp233, 19406901.
40. Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, Kozloff M. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 2008, 26:5326-5334. 10.1200/JCO.2008.16.3212, 18854571.
41. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680. 10.1200/JCO.2008.19.8135, 19114685.
42. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572. 10.1056/NEJMoa0808268, 19196673.
43. Bajetta E, Celio L, Ferrario E, Di Bartolomeo M, Denaro A, Dotti K, Mancin M, Bajetta R, Colombo A, Pusceddu S. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer. Ann Oncol 2007, 18:1810-1816. 10.1093/annonc/mdm347, 17823385.
44. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Guimbaud R, Delpero JR, Rivoire M, Quenet F, Portier G, Nordlinger B. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol 2008, 62:195-201. 10.1007/s00280-007-0588-3, 17901955.
45. Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis C, Vamvakas L, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006, 94:798-805. 10.1038/sj.bjc.6603011, 2361370, 16508637.
46. Zarate R, Rodriguez J, Bandres E, Patino-Garcia A, Ponz-Sarvise M, Viudez A, Ramirez N, Bitarte N, Chopitea A, Gacia-Foncillas J. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 2010, 102:987-994. 10.1038/sj.bjc.6605595, 2844042, 20216541.
47. Fornaro L, Vasile E, Masi G, Loupakis F, Baldi GG, Allegrini G, Salvatore L, Cremolini C, Cupini S, Cortesi E, et al. Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. Clin Colorectal Cancer 2012, 11:71-76. 10.1016/j.clcc.2011.06.013, 21903485.
48. Assenat E, Desseigne F, Thezenas S, Viret F, Mineur L, Kramar A, Samalin E, Portales F, Bibeau F, Crapez-Lopez E, et al. Cetuximab Plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial. Oncologist 2011, 16(11):1557-1564. 10.1634/theoncologist.2011-0141, 22016477.
49. Bruera G, Santomaggio A, Cannita K, Baldi PL, Tudini M, De Galitiis F, Mancini M, Marchetti P, Antonucci A, Ficorella C, Ricevuto E. " Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study. BMC Cancer 2010, 10:567. 10.1186/1471-2407-10-567, 2972284, 20958992.
50. Trarbach T, Schuette J. Dose escalating study of 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) and cetuximab in first-line therapy of patients with metastatic colorectal cancer. J Clin Oncol 2009, 27:abstr e15025.
51. Ychou M, Desseigne F. Preliminary results of a multicentre phase II trial evaluating cetuximab in combination with FOLFIRINOX (LV5FU + Irinotecan + Oxaliplatin) as first line treatment of metastatic colorectal cancer (mCRC) patients. Gastrointestinal Cancers Symposium 2009, 2009((Abstract-No: 295):abstr. 450.
52. Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010, 11:845-852. 10.1016/S1470-2045(10)70175-3, 20702138.
53. Garufi C, Torsello A, Tumolo S, Ettorre GM, Zeuli M, Campanella C, Vennarecci G, Mottolese M, Sperduti I, Cognetti F. Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadjuvant chemotherapy in colorectal liver metastases: POCHER trial. Br J Cancer 2010, 103:1542-1547. 10.1038/sj.bjc.6605940, 2990583, 20959822.
54. Falcone A, Loupakis F. FOLFOXIRI plus bevacizumab (BV) versus FOLFIRI plus BV as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary safety results of the phase III randomized TRIBE study by the Gruppo Oncologico Nord-Ovest (GONO). J Clin Oncol 2010, 28:abstr 3543.
55. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247. 10.1016/j.ejca.2008.10.026, 19097774.
56. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116. 10.1200/JCO.2008.20.6771, 19451431.
57. Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll HJ. Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer. J Clin Oncol 2011, 29:1465-1471. 10.1200/JCO.2010.33.6297, 21383294.
58. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer 2009, 45:275-280. 10.1016/j.ejca.2008.10.029, 19059773.
59. Piessevaux H, Schlichting M. Early tumor shrinkage for the prediction of efficacy of cetuximab in metastatic colorectal cancer: analysis from the CRYSTAL study. Ann Oncol 2010, 21:abstr. 596.
60. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010, 11:38-47. 10.1016/S1470-2045(09)70330-4, 19942479.
61. Wasan H, Adams RA. Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomized MRC COIN-b trial. J Clin Oncol 2012, 30:abstr 536.
62. Adams RA, Meade AM, Seymour MT, Wilson RH, Madi A, Fisher D, Kenny SL, Kay E, Hodgkinson E, Pope M, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011, 12:642-653. 10.1016/S1470-2045(11)70102-4, 3159416, 21641867.
63. Chibaudel B, Maindrault-Goebel F, Lledo G, Mineur L, Andre T, Bennamoun M, Mabro M, Artru P, Carola E, Flesch M, et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 2009, 27:5727-5733. 10.1200/JCO.2009.23.4344, 19786657.
64. Diaz-Rubio E, Gomez-Espana A, Massuti B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martinez de Prado P, Gallen M, et al. First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study. Oncologist 2012, 17:15-25. 10.1634/theoncologist.2011-0249, 22234633.